-- コリブリ・グローバル・エナジー（KEI.TO）は月曜日、原油価格の高騰を受け、オクラホマ州ティショミンゴ油田における3本の水平坑井（全長1.5マイル）の掘削計画を前倒しすると発表した。 同社は、クリフトン・マック11-14-1H、クリフトン・マック11-14-2H、クリフトン・マック11-14-3Hの各坑井の掘削を来週開始する予定だと述べた。 その結果、コリブリは2026年の平均生産量が前年比10～20%増の1日当たり4,400～4,800バレル相当になると見込んでいる。売上高は30～39%増の7,400万～7,900万米ドルになると予測している。 また、調整後EBITDAは31～43%増の5,500万～6,000万米ドルになると予測している。すべての予測は、原油価格を1バレル74ドルと仮定しています。 「生み出されるキャッシュフローは、債務返済、株主への資本還元、そして今年の掘削井増設に充当されます」と、最高経営責任者（CEO）のウルフ・レゲナー氏は述べています。「原油価格が当社の基本予測シナリオを上回る水準で推移すれば、フリーキャッシュフローはさらに増加し、より多くの選択肢が生まれるでしょう。」
Related Articles
Asia
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
$ASX:ONE
Asia
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
$ASX:PAR
Asia
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.
$SHA:600703